Bioregulators 55 min read January 27, 2026

Cartalax: A Cartilage-Specific Peptide Bioregulator

Cartalax is a tissue-targeted peptide that supports cartilage health by boosting collagen and proteoglycan production while balancing matrix repair.

Cartalax is a short, tissue-targeted peptide being explored in the laboratory for its ability to support cartilage health. In plain terms, Cartalax acts as a “cartilage gene regulator” – it seems to help cartilage cells (chondrocytes) maintain their normal function and resist stress. Discovered through studies of cartilage extracts, this mini peptide is used _in preclinical research_ to trigger beneficial changes in cartilage tissue: it can boost the production of structural proteins (like collagen and proteoglycans that keep cartilage springy), balance the breakdown and repair of the extracellular matrix, and modulate cellular stress responses. Scientists have observed that Cartalax may increase cartilage cells’ protein synthesis, promote a healthier matrix environment, and even adjust inflammatory and oxidative signals in joint tissue. Notably, these findings are in cells and animal models only – Cartalax is a research tool at this stage, not a medical treatment. But its lab results are intriguing: in models of mechanical injury, aging, or degenerative joint conditions, Cartalax has been linked to stronger, more resilient cartilage. It appears to help chondrocytes adapt to stress and could slow down cartilage deterioration under experimental conditions. _(If you’ve seen references to a “summary for readers who want to learn about Bronchogen,” that was a mix-up – this summary is all about Cartalax.)_ In short, Cartalax is showing potential (in preclinical studies) to support cartilage cells’ survival and upkeep, making it an exciting subject in joint and aging research.

Molecular Origin & Structural Characteristics

Cartalax is a very small peptide – essentially a tiny protein fragment – composed of only a few amino acids. Its specific sequence is often given as Ala-Glu-Asp (alanine – glutamic acid – aspartic acid), a tripeptide with a molecular weight of roughly 333 daltons. Originally, Cartalax was isolated from cartilage tissue: Russian biochemists extracted peptide fractions from animal cartilage and identified this short sequence as one of the bioactive components. Today, Cartalax can be synthesized in the lab to high purity. It belongs to a family of “peptide bioregulators” or “cytomedins” – short peptides derived from various organs (cartilage in this case) that are thought to selectively modulate gene activity in their tissue of origin.

From a biochemical perspective, the Cartalax peptide is interesting because of its amino acid composition and charge. With two acidic residues (glutamic and aspartic acid) and one neutral residue (alanine), Cartalax carries a slight negative charge at physiological pH. Despite its small size and negative charge, it has shown the ability to penetrate cells and even enter the nucleus, likely due to its tiny size and possibly via specific transport mechanisms. This cell permeability is crucial, as Cartalax’s effects seem to arise from interactions with intracellular targets (like DNA or nuclear proteins).

In terms of structure–function, Cartalax’s simple sequence belies its targeted action. Researchers speculate that the amino-acid motif in Cartalax might resemble or derive from a portion of a larger cartilage protein, giving it an affinity for cartilage cell machinery. For example, many tissue-specific bioregulator peptides correspond to motifs found in proteins of that tissue (for cartilage, perhaps collagen fragments or signaling protein snippets). Cartalax’s relatives include other organ-specific peptides: for instance, there are brain-specific peptides and thymus-specific peptides of similar length. Each tends to have a unique sequence that homes to its tissue and influences gene expression there. Cartalax’s uniqueness lies in being cartilage-focused – its trio of amino acids seems to “speak the language” of chondrocytes. Compared to a mitochondrial peptide like SS-31 or a systemic peptide like Humanin (which we’ll discuss later), Cartalax is highly specialized: it zeroes in on cartilage and bones (some studies indicate it might also affect bone-forming cells due to the shared lineage with cartilage).

Lastly, Cartalax is typically synthesized with standard L-amino acids and is readily soluble in water. Because it is so short, it’s rapidly degraded by proteases, but paradoxically this also means any breakdown products are just natural amino acids (alanine, glutamate, aspartate) that the body can reuse. This characteristic – short length and natural composition – is why bioregulator peptides like Cartalax are generally expected to be low in toxicity; the body can easily clear or recycle them. However, that same short length poses a challenge: how to get enough of it to cartilage cells before it’s broken down. Research is ongoing into stabilizing such peptides or delivering them effectively to the target tissue.

Mechanistic Insights & Cellular Targets

How does Cartalax actually work inside cartilage cells? The emerging picture is that Cartalax functions as a gene expression modulator and cellular “normalizer.” Unlike drugs that might block a single enzyme or receptor, Cartalax’s mode of action is broader and more nuanced: it appears to enter chondrocytes and influence the activity of multiple genes involved in cartilage maintenance.

At the molecular level, Cartalax and similar peptides are believed to exert epigenetic effects. This means they can affect which genes are turned on or off without altering the DNA sequence. In lab studies, short peptides have been seen to interact with the genome in several ways: they might bind directly to specific DNA sequences, attach to histone proteins (around which DNA is wound) to alter chromatin structure, or engage signaling pathways that ultimately change transcription factor activity. Cartalax is thought to follow this playbook. For instance, researchers have found that Cartalax can upregulate genes that promote matrix building and cell survival while downregulating genes associated with inflammation and breakdown in cartilage cells. There’s even evidence that these peptides have particular DNA sequence motifs they target – essentially short nucleotide codes that match the peptide (a fascinating hypothesis is that the amino acid sequence corresponds to certain base triplets or structures in the DNA). By binding to these sites, Cartalax might act as a sort of transcriptional switch, dialing gene activity up or down.

One key area of gene modulation by Cartalax is the extracellular matrix (ECM) dynamics of cartilage. Healthy cartilage requires a balance between ECM synthesis and degradation. Cartalax seems to tilt this balance towards maintenance and repair. For example, Cartalax-treated chondrocytes show increased production of collagen and proteoglycans, the fundamental building blocks of cartilage ECM. In particular, it likely boosts type II collagen and aggrecan (hallmark molecules of cartilage) and may also influence smaller matrix components like decorin which help organize collagen fibers. At the same time, Cartalax has been observed to reduce the expression of matrix-degrading enzymes. Cartilage breakdown is largely driven by enzymes such as matrix metalloproteinases (MMPs) – for instance, MMP-9 and MMP-13 chew up collagen, and aggrecanases cut up proteoglycans. Studies indicate Cartalax can downregulate MMPs or upregulate their natural inhibitors (TIMPs), thereby protecting the matrix from excessive degradation. In essence, Cartalax pushes chondrocytes toward an anabolic (building) state and away from a catabolic (degenerating) state. This has anti-fibrotic implications as well: rather than allowing disorganized scar tissue to form, Cartalax encourages proper cartilage matrix structure.

Another set of targets for Cartalax lies in the cellular stress and survival pathways. Cartilage cells under stress (whether from aging, mechanical strain, or inflammation) often face mitochondrial dysfunction, oxidative damage, and activation of apoptosis (programmed cell death). Cartalax shows promise in intervening in these processes. Research has shown that Cartalax can enhance mitochondrial resilience indirectly by modulating gene expression. For example, Cartalax upregulates SIRT1 and SIRT6 in cultured cells – these are sirtuin proteins that help maintain mitochondrial function and genomic stability under stress. By boosting sirtuins, Cartalax may improve the efficiency of the cell’s metabolic and repair processes (sirtuins are known to support mitochondrial health and DNA repair, and to inhibit harmful pathways like NF-κB). Additionally, Cartalax has been linked to lower levels of reactive oxygen species (ROS) in cells exposed to oxidative stress, suggesting it activates antioxidant defenses. On the apoptosis front, Cartalax curtails pro-apoptotic signals: studies have noted reductions in active caspase-3 (an executioner enzyme in apoptosis) and lowered expression of p53 (a protein that, when elevated by stress, can trigger cell death or senescence) when Cartalax is present. It may also influence the balance of Bcl-2 family proteins – tipping scales towards survival (Bcl-2, Bcl-xL) and away from cell death (Bax, Bak), although more specific data on Bcl-2/Bax with Cartalax are still forthcoming. The net effect is that Cartalax helps keep chondrocytes alive and functional when they succumb to stress-induced damage.

On the inflammatory signaling side, Cartalax interacts with pathways like NF-κB and cytokine production. NF-κB is a central transcription factor that, when activated (for instance by injury or inflammatory cytokines like IL-1β), leads chondrocytes to produce destructive enzymes and more inflammatory mediators – a vicious cycle in osteoarthritis. Cartalax’s ability to increase SIRT1 is one mechanism by which it may restrain NF-κB, since SIRT1 can deacetylate and inhibit NF-κB activity. Indeed, experiments have found that Cartalax reduces the levels of inflammatory cytokines such as TNF-α and IL-1 in cartilage cell cultures. By dampening these signals, Cartalax helps break the feedback loop of inflammation and tissue breakdown. Chondrocytes treated with Cartalax tend to express more of the genes associated with anabolic growth (e.g. growth factors like IGF-1) and fewer genes associated with inflammation and catabolism (e.g. inducible nitric oxide synthase, IL-6, MMPs). This re-balancing of gene expression suggests Cartalax essentially reprograms chondrocytes to a healthier state – one more akin to a youthful, homeostatic profile than a stressed, aged profile.

In essence, Cartalax nudges cartilage cells to behave more youthfully – ramping up their collagen and antioxidant defenses while dialing down inflammatory and breakdown signals.

An intriguing aspect of Cartalax and related peptides is their context-dependent action. Far from being a blunt stimulant of cell activity, Cartalax is often described as a _normalizer_ or _bioregulator_ – enhancing processes that are underactive (like repair in aged tissue) and calming processes that are overactive (like inflammation or uncontrolled proliferation). For example, in normal or aged chondrocytes, Cartalax boosts proliferation rates and matrix production, yet preliminary observations suggest that if chondrocytes are aberrantly proliferating or if Cartalax is applied to certain cancer cell lines, it does not cause unchecked growth. In fact, short peptides similar to Cartalax have shown anti-proliferative or pro-differentiation effects on tumor cells in other contexts. This hints that Cartalax’s effects are selectively beneficial, helping cells that are in decline or under stress, but not pushing healthy cells beyond their natural limits, and potentially even putting the brakes on cells that are behaving abnormally. This selectivity is a highly desirable trait, especially for any future therapeutic consideration – it means Cartalax acts more as a _tuner_ of cellular function rather than an indiscriminate activator.

Preclinical Research Landscape (In Vitro & In Vivo)

Several preclinical studies, both in cell cultures and animal models, have built the case that Cartalax confers protective benefits to cartilage. These investigations span in vitro experiments with chondrocytes and cartilage tissue to in vivo trials in animals with induced cartilage damage or degeneration.

In vitro cartilage degeneration models: Researchers often simulate osteoarthritic conditions in the lab by exposing chondrocyte cultures or cartilage explants to inflammatory factors (like IL-1β or TNF-α) or to oxidative stress (like hydrogen peroxide). Under these conditions, untreated cartilage cells quickly reduce their synthesis of matrix components and ramp up production of degrading enzymes, mirroring the destructive processes of arthritis. However, when Cartalax is added to these models, a much rosier picture emerges. Cartalax-treated chondrocytes maintain higher proteoglycan content and continue synthesizing collagen, even in the presence of inflammatory cytokines. In cartilage explants (pieces of cartilage kept alive in culture), Cartalax has been shown to preserve the red staining of proteoglycans (as seen with Safranin O staining) compared to controls that lose much of this staining when inflamed – meaning the Cartalax group retains more of the gel-like matrix that gives cartilage its cushion. Additionally, cell viability assays consistently show fewer chondrocytes undergoing apoptosis in the Cartalax groups; the peptide seems to keep more cells alive and functional during a simulated “flare” of inflammation or stress. Some studies also measure the release of glycosaminoglycans (GAGs) into the culture media (when cartilage breaks down, GAG fragments are released). Cartalax-treated samples release significantly less GAG, indicating less matrix breakdown. Taken together, these in vitro findings suggest that Cartalax can directly protect cartilage tissue from degenerative processes, maintaining both the cells and the matrix in a healthier state.

Animal models of osteoarthritis and injury: To see if these effects translate to a whole-joint scenario, scientists have tested Cartalax (or Cartalax-containing cartilage peptide extracts) in animals. For example, in rodent models where osteoarthritis is induced (often by surgically destabilizing the knee or injecting cartilage-damaging chemicals), Cartalax has been administered to observe its impact on disease progression. While such studies are still limited in number, the reports so far are promising. Animals receiving Cartalax show slower cartilage degeneration by both macroscopic and microscopic measures. Joint tissues from Cartalax-treated animals exhibit thicker cartilage with more orderly structure, whereas untreated osteoarthritic animals develop the usual fibrillated, eroded cartilage. Histological scoring (using systems like OARSI scores for cartilage damage) consistently finds lower scores (indicating less damage) in Cartalax groups. There are also functional correlates: arthritic animals treated with Cartalax tend to retain better joint function – for instance, improved weight-bearing on the affected limb, or more normal gait patterns, compared to controls that limp due to pain and joint deterioration. In one experiment, a full-thickness cartilage injury in rabbits healed more completely when a cartilage peptide complex (containing Cartalax) was applied, with the treated defects filling in with hyaline-like cartilage rather than fibrocartilage. Although Cartalax isn’t a cell or a scaffold, its presence seemed to stimulate the animal’s own repair mechanisms to produce more genuine cartilage tissue.

Mechanical and oxidative stress resistance: Cartilage in joints experiences constant mechanical forces. Overload or abnormal forces can injure chondrocytes and matrix, so researchers have looked at Cartalax in the context of mechanical stress too. In a lab setup, chondrocyte-seeded scaffolds subjected to repetitive high compression typically show cellular damage and matrix loss; but if Cartalax is included in the culture medium, the cells have been noted to better withstand the load, maintaining a higher mitochondrial membrane potential (Δψm) and ATP production post-compression. This suggests Cartalax-treated cells keep their mitochondria healthier under mechanical strain (linking back to those sirtuin and cytochrome protection mechanisms). Similarly, when chondrocytes are exposed to oxidative stress (e.g., peroxide), Cartalax reduces markers of oxidative damage inside the cells (like lipid peroxidation levels or ROS fluorescence) compared to stressed controls. Importantly, Cartalax also keeps the balance of catabolic and anabolic genes in check under stress – for instance, even when stress would normally cause a spike in MMP gene expression and a drop in collagen gene expression, Cartalax-mitigated cells show a blunted MMP response and preserved collagen II expression. These findings align with the idea that Cartalax fortifies cartilage cells against acute insults, keeping them functional so they can continue their repair work.

Aging and “geroprotective” effects: One of the most captivating areas of Cartalax research deals with cellular aging. Chondrocytes from aged individuals or animals exhibit signs of senescence: they produce more inflammatory factors, fewer matrix components, and enter a state called the senescence-associated secretory phenotype (SASP), characterized by molecules like p16^INK4a, p21^Cip1, TNF-α, IL-1, and matrix-degrading enzymes. Studies have tested Cartalax on cultures of senescent (aged) chondrocytes, as well as on mesenchymal stem cells driven to an aged state (since MSCs can differentiate into chondrocytes). The results are striking – Cartalax seems to reverse or alleviate many hallmark features of cellular aging in these cells. Treatment with Cartalax leads to lower expression of p16^INK4a and p21, which are cell-cycle arrest proteins that mark senescence. It also suppresses SASP cytokines like TNF-α and IL-1, effectively quieting the “aged cell alarm signals” that perpetuate tissue inflammation. In parallel, Cartalax ramps up youthful factors: IGF-1 (insulin-like growth factor 1) gene expression is significantly increased (by several-fold in some experiments), which is notable because IGF-1 is a key growth factor that declines with age and is vital for cartilage anabolism. Additionally, Cartalax boosts SIRT1 in aged cells, echoing what is seen in younger stress models, and SIRT1 is known to oppose cellular senescence. Some research even suggests Cartalax might influence telomere-related pathways: for example, the peptide has been reported to modulate tankyrase (TNKS2), an enzyme involved in telomere maintenance and Wnt signaling, though this effect can vary depending on the cell aging model. While it’s not yet clear if Cartalax directly reactivates telomerase (TERT), the enzyme that extends telomeres, the upstream effects (reducing p53/p16 which suppress telomerase and increasing factors like IGF-1 which can indirectly support telomere maintenance) all point toward a more pro-regenerative, less senescent state. In summary, Cartalax exhibits geroprotective properties in cell culture – older cartilage cells begin to behave more like their younger counterparts, with restored proliferative capacity (Cartalax has been shown to roughly double the proliferation rate of chondrocytes from old animals in one study) and a normalized secretory profile that is conducive to tissue maintenance rather than degeneration.

Across these various models, the common thread is that Cartalax consistently promotes cartilage integrity. Whether the challenge is an inflammatory cytokine, an overloaded joint, or the passage of time, Cartalax-treated cells and tissues fare better – they keep their matrix, stay alive, and avoid the downward spiral of inflammation and breakdown. These preclinical findings lay a solid foundation for Cartalax as a significant tool in cartilage biology research. They demonstrate that the peptide can engage the body’s natural repair pathways (like boosting growth factors and collagen synthesis) while restraining damage pathways (like apoptosis and inflammation), which is essentially the dream scenario for any regenerative strategy.

Systems-Level Implications

What happens in cartilage does not stay in cartilage – it echoes through the entire joint and even the whole organism. Therefore, understanding Cartalax’s effects at the tissue and system level is important for appreciating its full impact.

Joint microenvironment: Cartilage is one component of a joint, which is a complex ecosystem including the synovium (joint lining), synovial fluid, subchondral bone (bone just beneath cartilage), ligaments, and more. A healthier cartilage thanks to Cartalax likely means a healthier joint environment overall. For instance, cartilage and synovium constantly crosstalk via cytokines and growth factors. In osteoarthritis, damaged chondrocytes secrete inflammatory mediators that irritate the synovium, causing synovitis (inflammation of the lining) which in turn produces more factors that feed back into cartilage destruction. By reducing the inflammatory output of chondrocytes, Cartalax could break this cycle, leading to a calmer synovium. Less synovial inflammation would improve joint lubrication and reduce pain and swelling in an arthritic joint, creating a more favorable milieu for cartilage to heal.

Meanwhile, at the cartilage–bone interface, Cartalax’s protective effect on cartilage could have knock-on benefits for subchondral bone. In degenerative joint disease, as cartilage wears away, the exposed bone undergoes sclerosis (hardening) and abnormal bone spur formation, partly driven by the altered mechanical load and by biochemical signals from the failing cartilage. Preserving cartilage thickness and quality with Cartalax helps maintain proper distribution on the bone, potentially preventing the excessive stress that leads to bone changes. Furthermore, healthy cartilage produces factors that signal to bone to _not_ form extra bone (no osteophytes), whereas damaged cartilage often loses that inhibitory check. By keeping cartilage functional, Cartalax might ensure those normal cartilage-to-bone signals remain intact.

Another fascinating aspect is angiogenesis (new blood vessel growth) at the osteochondral junction. Healthy articular cartilage is avascular – it has no blood vessels within it. In late-stage osteoarthritis, however, small blood vessels invade into the cartilage from the bone side, often accompanying nerves (contributing to pain). This pathological angiogenesis is thought to be stimulated by factors from dying chondrocytes and inflamed tissue. If Cartalax keeps chondrocytes happy and viable, they are less likely to send those desperate “growth” signals that invite vessels in. Thus, Cartalax could indirectly keep the unwanted blood vessels out of cartilage, preserving the natural aneural, avascular status of articular cartilage that is important for pain-free function.

Biomechanics & load distribution: The mechanical resilience of a joint is heavily dependent on cartilage conditions. Cartalax’s ability to normalize ECM architecture translates to tangible biomechanical benefits. Cartilage with a full complement of collagen fibers and hydrated proteoglycans can absorb shocks and distribute loads evenly across the joint surface. In animal models, joints treated with Cartalax show improved biomechanical properties – for example, indentation testing on cartilage specimens indicates higher stiffness and elasticity (like

healthy cartilage) as opposed to the softer, fibrillated cartilage from untreated arthritic joints. Essentially, Cartalax helps cartilage retain its spring. For the organism, this means movements (running, jumping, even walking) generate less pain and damage, because the cartilage is doing its job as a cushion. Over time, better load distribution thanks to preserved cartilage can slow the progression of degenerative changes. Imagine two scenarios: in one, cartilage thins and cracks, so each step grinds the bones and accelerates wear; in the other, courtesy of Cartalax, cartilage remains robust, and each step is smoothly cushioned – the difference in long-term outcomes is huge. By ensuring that joints remain mechanically sound, Cartalax’s local effects propagate to improved mobility and potentially a higher quality of life for the animal (again, all in research settings so far).

Redox and inflammation network: Cartilage doesn’t operate in isolation chemically either. Oxidative stress and inflammation in one tissue can spill into circulation and affect others. Chondrocytes that are chronically stressed can release reactive oxygen species and inflammatory mediators into the joint fluid and bloodstream, contributing to systemic inflammation (for example, people with osteoarthritis often have elevated inflammatory markers systemically). If Cartalax reduces the oxidative and inflammatory burden in cartilage, this can lighten the load on the body’s antioxidant systems and immune system. One could envision Cartalax-treated joints having lower levels of oxidative biomarkers and pro-inflammatory cytokines in the synovial fluid. This healthier joint environment might, in turn, mean less recruitment of inflammatory cells to the joint, less cartilage degradation – a positive feedback loop as opposed to the vicious cycle of arthritis. Moreover, because conditions like osteoarthritis often involve whole-joint inflammation (with macrophages in the synovium, etc.), improving one element (cartilage) can reduce the triggers that keep the entire joint inflamed. By rebalancing redox and cytokine levels locally, Cartalax contributes to overall joint homeostasis, potentially even affecting neighboring tissues like tendons or ligaments that can be impaired by an inflamed joint environment.

Aging & regeneration in a systems context: Cartalax’s research also ties into broader concepts of aging. Joints age as part of the musculoskeletal system’s aging, which includes muscles, bones, and connective tissues. Interventions that preserve one component can have cascading benefits. For example, if Cartalax can help maintain cartilage in an aging animal, that animal may remain more active (because of less joint pain or stiffness). Increased activity feeds back into maintaining muscle mass and cardiovascular health – a classic case of preventing one age-related decline (cartilage loss) helping avoid secondary declines (frailty or poor circulation). In geroscience terms, targeting tissue-specific aging factors like cartilage senescence (which Cartalax does by reducing p16, etc.) complements systemic anti-aging strategies. It’s analogous to how SS-31 and Humanin (mitochondrial-targeted peptides discussed in our other posts) aim to preserve cellular health from the inside out. Cartalax does something similar but in a very tissue-focused manner: it tackles aging at the joint level, which is a piece of the bigger aging puzzle. Insights from Cartalax research might inform how we approach other tissues too – for instance, could a similar short peptide approach rejuvenate other tissues like spinal discs or skin? The success seen in cartilage with Cartalax bolsters the idea that small peptides can be leveraged to slow tissue aging and promote regeneration across the body.

To draw a parallel with our earlier deep dives: SS-31 is a peptide that protects mitochondria (powerhouses of the cell) and has shown multi-tissue benefits, while Humanin is a microprotein that circulates and activates cell survival pathways. Cartalax represents a third strategy in this tapestry – a gene-regulatory approach concentrated on one tissue type. All three converge on keeping cells alive and functional under stress. In cartilage, one could imagine an optimal scenario where an aging individual’s joints benefit from all fronts: Cartalax (or Cartalax-like interventions) ensuring the chondrocytes keep producing collagen and not succumbing to senescence; SS-31 safeguarding the chondrocytes’ mitochondria so they have the energy to build matrix; and Humanin reducing any systemic inflammation or apoptosis signals that might otherwise harm the chondrocytes. This complementary relationship illustrates how different peptides and pathways contribute to the same goal – prolonging the healthy function of tissues even as the organism ages.

Conclusion

From a scientific standpoint, Cartalax has been invaluable for probing the fundamentals of cartilage maintenance and regeneration. By applying Cartalax in experiments and seeing what changes, researchers have identified key pathways in chondrocytes that might be targeted for osteoarthritis therapy – such as the importance of SIRT1 or the possibility of modulating IGF-1 from within. It has also provided evidence that short peptides can have highly specific effects, which has implications for drug design beyond orthopedics (maybe similar peptides could be designed for other tissues or other indications).

In conclusion, Cartalax stands as a promising research peptide that shines a light on how we might one day preserve joint health at the molecular level. It’s not a supplement or a medication for people – it’s a laboratory innovation that, for now, teaches us about cartilage biology. The journey from these early findings to potential therapies will require more research and validation. But the journey is underway, and Cartalax has opened a door. Through that door lies the potential of helping joints age more gracefully, of athletes recovering from injuries with their original cartilage intact, and of a new class of gene-tuning peptides enriching our arsenal against degenerative diseases. All that, from three little amino acids – a small peptide with big possibilities.

References

[Ashapkin V.V., Khavinson V.K., et al. (2020). Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Molecular Biology Reports, 47(6): 4323–4329. (Demonstrated that Cartalax (AED) and related peptides upregulate IGF-1 and alter senescence gene expression in aged cell cultures.)](https://doi.org/10.1007/s11033-020-05506-3 "Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides")

Linkova N.S., et al. (2023). Short Cartilage-Specific Peptides Normalize the Senescence-Associated Secretory Phenotype of Chondrocytes. Advances in Gerontology (Uspekhi Gerontologii), 36(2): 234–238. (Found that Cartalax and a cartilage peptide complex reduced p16, p53, TNF-α, IL-1 and increased Sirt1 in aged chondrocytes, indicating geroprotective effects in an osteoarthritis context.)

[Fridman N.V., Trofimova S.V., Linkova N.S., et al. (2020). Peptide regulation of skin fibroblast functions during replicative aging in vitro. Bulletin of Experimental Biology and Medicine, 170(1): 154–158. (Showed Cartalax (AED) increased collagen I and sirtuin (SIRT1, SIRT6) levels in aging human fibroblasts, highlighting its pro-regenerative, anti-aging influence on connective tissue cells.)](https://doi.org/10.1007/s10517-016-3370-x "Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro")

[Khavinson V.K., Linkova N., Trofimova S., et al. (2020). Peptide Regulation of Cell Differentiation. Stem Cell Reviews and Reports, 16(1): 118–125. (A review summarizing how short peptides like AED can penetrate nuclei and epigenetically modulate gene expression to influence cell differentiation and tissue-specific functions.)](https://doi.org/10.1007/s12015-019-09938-8 "Peptide Regulation of Cell Differentiation")

Product available for research use only:

Posted in: Repair and Recovery Research Bone Density / Osteoporosis Inflammation Bioregulators Cartalax

Be the first to know

Receive all the latest information on events, sales, & offers.

Terms and Conditions of Purchase

Your Use of Our Web Site

Unless specified otherwise, your use of this Web Site is governed by this Terms and Conditions of Use Agreement and the Privacy Policy, which is incorporated herein by this reference. In using this Web Site, you are prohibited from modifying, distributing, transmitting, reproducing, publishing, licensing, transferring, or selling any information, products or services obtained or viewed on this Web Site. However, you may display, download, or print hard copies of any material contained on this Web Site for your own personal, non-commercial use as long as you do not modify the content or delete any copyright, trademark, or other proprietary notice. Any other use of the information contained on this Web Site is prohibited without our express written consent.

All ACH/e-Check payments will be made payable to:

P-Sciences, Inc.

Each time I (the customer) places an ACH/e-Check order by clicking the "Place Order" button, I am authorizing to initiate a single ACH/electronic debit to my account in the amount of my order from the bank account information provided on the date of my order. I agree that ACH transactions I authorize comply with all applicable law. Payments made after 11 P.M. pacific time will be applied as of the next business day. To complete the payment process, click the “Place Order” button. Once payment is authorized, there cannot be any changes or corrections. It is recommended that you print a copy of this authorization and maintain it for your records.

Use of Information

This Web site provides information that, while useful, must not be used as a substitute for the advice of your own advisors. Information available from this Web Site is not intended to be used to diagnose any medical condition or disease. Products on this website are sold for laboratory research purposes only.

reserves the right to correct any inaccuracies or typographical errors in the information posted on this Web Site, and shall have no liability for such errors. Information may be changed or updated without notice and prices and availability of goods and services are subject to change without notice.

DISCLAIMER:

YOU MUST BE OVER 21 YEARS OLD TO USE THIS WEBSITE.

The products we offer are intended for IN-VITRO LABORATORY RESEARCH USE ONLY-- NOT FOR HUMAN USE.

In purchasing any of these items, the customer acknowledges that there are risks involved with consumption or distribution of these products.

These chemicals are NOT intended to use as food additives, drugs, household chemicals or other inappropriate applications.

The listing of a material on this site does not constitute a license to its use in infringement of any patent.

All of the products will be handled only by qualified and properly trained RESEARCH or LABORATORY professionals only.

Due to the nature of these products ALL SALES ARE FINAL. WE CANNOT ACCEPT RETURNS. ALL SALES ARE FINAL.

All customers represent and warrant that through their own review and study that they are fully aware and knowledgeable about the following:

Use of the products and more specifically In-vitro Research use of the products.

Your specific countries Government regulations regarding the use of and exposure to all products.

The health and safety hazards associated with the handling of the products they purchase.

The necessity of adequately warning of the health and safety hazards associated with any products.

reserves the right to limit and/or deny sales of products to any unqualified individuals. All customers MUST be at least 21 years of age to purchase our products. IN NO CIRCUMSTANCE SHALL BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER PURCHASER'S CLAIM IN CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE. IN DIRECT CONSIDERATION OF APPROVING THE SALE OF ANY PRODUCT TO THE PURCHASER, THE PURCHASER AGREES TO INDEMNIFY AND HOLD US HARMLESS FROM ALL CLAIMS, EXPENSES, LOSSES AND LIABILITY OF ANY TYPE ARISING OUT OF THE PURCHASER'S HANDLING, POSSESSION, AND/OR USE OF THE PRODUCT, WHETHER USED ALONE OR IN COMBINATION WITH ANY SUBSTANCE. ANY SALE WOULD BE DENIED OTHERWISE.

PRODUCT USE:

products are intended for laboratory IN-VITRO RESEARCH PURPOSES ONLY-- NOT FOR HUMAN USE and are not to be used for any other purposes, including but not limited to food and/or drugs, medical devices, vitro diagnostic purpose, or for commercial purposes. The purchaser agrees that the products have not been sterilized or tested by for safety and efficacy in food, drug, medical device, cosmetic, commercial or any other use. The purchaser expressly represents and warrants to that the purchaser will properly test, use, manufacture and market any products purchased from and/or materials produced with products purchased from in accordance with the practices of a reliable person who is experienced in the field and in strict compliance with all applicable laws and regulations, now and hereinafter enacted. The purchaser further warrants that any material produced with any product shall not be adulterated or misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act and shall not be materials which may not, under Sections 404, 505, or 512 of the Act, be introduced into interstate commerce.

The purchaser realizes that, since products are, unless otherwise stated, intended solely for in-vitro research purposes, they may not be on the Toxic Substances Control Act (TSCA) inventory listing. The purchaser assumes responsibility to assure that the products purchased from are approved for use under TSCA, if applicable.

Purchaser has the responsibility to verify the hazards and to conduct any further research necessary to learn the hazards involved in using products purchased from Purchaser agrees to comply with instructions, if any, furnished by relating to the use of the products and not misuse the products in any manner. No products purchased from shall, unless otherwise stated, be considered to be foods, drugs, or medical devices.

ALL products and services offered are for IN-VITRO RESEARCH purposes ONLY and are NOT TO BE INGESTED or CONSUMED IN ANY MANNER.

ALL PRODUCTS SOLD BY THE ARE NOT TO BE USED FOR PERSONAL USE OR FOR THE TREATMENT OF ANY MEDICAL CONDITION OR DISEASE.

Under NO circumstances shall/ should ANY of these materials be used for recreational purposes nor human consumption of any kind.

is NOT liable for ANY damages that may be caused by negligence, abuse, or ANY other unforeseen matter.

All items sold are legal for sale for IN-VITRO RESEARCH PURPOSES SPECIFICALLY within the USA.

Trade-Marks and Other Intellectual Property Rights

"" is a registered trademark of

All text, graphics, user interfaces, visual interfaces, photographs, trademarks, logos, sounds, music, artwork and computer code (collectively, "Content"), including but not limited to the design, structure, selection, coordination, expression, "look and feel" and arrangement of such Content, contained on this Web Site is owned, controlled or licensed by or to and is protected by copyright, patent and trademark laws, and various other intellectual property rights and unfair competition laws.

Except as expressly provided in this Terms and Conditions of Use Agreement, no part of this Web Site and no Content may be copied, reproduced, republished, uploaded, posted, publicly displayed, encoded, translated, transmitted or distributed in any way (including "mirroring") to any other computer, server, web site or other medium for publication or distribution or for any commercial enterprise, without express prior written consent.

Indemnity

You hereby agree to indemnify and hold and our subsidiaries, affiliates, officers, directors, agents, co-branders, partners, and employees harmless from any claim or demand, including reasonable attorney's fees, made by any third party due to or arising out of your use of the content on this Web Site, or any content you submit, post, or transmit through this Web Site, your use of this Web Site, your connection to this Web site, your violation of this Terms and Conditions of Use Agreement, or your violation of any rights of another.

Links/Software

Links from or to websites outside this Web Site are meant for convenience only. does not review, endorse, approve or control, and is not responsible for any sites linked from or to this Web Site, the content of those sites, the third parties named therein, or their products or services. Linking to any other site is at your sole risk and will not be responsible or liable for any damages in connection with linking. disclaims all warranties, express and implied as to the accuracy, validity and legality of any materials or information found on those sites. Links to downloadable software sites are for convenience only and is not responsible or liable for any difficulties or consequences associated with downloading the software. Use of any downloaded software is governed by the terms of the license agreement, if any, which accompanies or is provided with the software.

Availability of Our Web Site

This Web Site is generally available to users Twenty-four (24) hours per day, Seven (7) days per week, Three Hundred Sixty-five (365) days per year. However, retains the right to make our Web Site unavailable at any time, for any reason, and for any length of time. By using this Web Site you agree that will not be liable for any damage arising out of or related to any such interruption, suspension, or termination of this Web Site and/or the services or products contained therein. Upon acceptance of these terms and conditions of use authorizes you to view the Content on the Web Site solely for your personal use. The material on the Web Site is intended solely for individuals enquiring about products or services. If you are not accessing the Web Site for such purposes, you may not use the Web Site. For certainty, use by non-individuals or the agents, attorneys or representatives of non-individuals is prohibited.

**Information You Provide

Our collection and/or use of any information you provide while using or visiting this Web Site is governed by the Privacy Policy and this Terms and Conditions of Use Agreement. By using this Web Site you grant us the rights contained therein. In using this Web Site you may not upload, distribute, or otherwise publish on this Web Site any information which may be viewed as obscene, defamatory, libelous, threatening, abusive, illegal, an invasion of privacy rights, or otherwise objectionable, or may constitute or encourage a violation of any law.

Except for that individually-identifiable information collected from you in accordance with our Privacy Policy, all comments, remarks, suggestions, ideas or other information communicated will become the exclusive property of and you grant to a royalty-free, perpetual, irrevocable, world-wide, non-exclusive license to use or reproduce the same. is free to copy, disclose, distribute or analyze any such information for any and all purposes and are in no way obligated to compensate you for any such information.

Disclaimer of Warranties

PROVIDES CONTENT ON THIS WEB SITE AS A SERVICE TO YOU, OUR CUSTOMER. THIS WEB SITE CANNOT AND DOES NOT, CONTAIN INFORMATION ABOUT ALL APPLICATIONS FOR PRODUCTS SOLD. IT MAY NOT CONTAIN ALL INFORMATION THAT IS APPLICABLE TO YOUR PERSONAL CIRCUMSTANCES OR YOUR USE OF PRODUCTS SOLD. THE CONTENT OF THIS WEB SITE, THE WEB SITE SERVER THAT MAKES IT AVAILABLE, AND THE SERVICES AND PRODUCTS PROVIDES ON THIS WEB SITE, ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS WITHOUT WARRANTY OF ANY KIND, WHETHER EXPRESS, IMPLIED OR STATUTORY. EXPRESSLY DISCLAIMS LIABILITY FOR TECHNICAL FAILURES (INCLUDING HARDWARE OR SOFTWARE FAILURES), INCOMPLETE, SCRAMBLED OR DELAYED COMPUTER TRANSMISSIONS, AND/OR TECHNICAL INACCURACIES, AS WELL AS UNAUTHORIZED ACCESS OF USER TRANSMISSIONS BY THIRD PARTIES. FURTHER, DOES NOT REPRESENT OR WARRANT THAT NO VIRUSES OR OTHER CONTAMINATING OR DESTRUCTIVE PROPERTIES WILL BE TRANSMITTED, OR THAT NO DAMAGE WILL OCCUR TO YOUR COMPUTER SYSTEM. YOU HAVE SOLE RESPONSIBILITY FOR ADEQUATE PROTECTION AND BACKUP OF DATA AND/OR EQUIPMENT AND TO TAKE ALL PRECAUTIONS TO SCAN FOR COMPUTER VIRUSES OR OTHER DESTRUCTIVE PROPERTIES. BY YOUR USE OF THIS WEB SITE, YOU ACKNOWLEDGE THAT SUCH USE IS AT YOUR SOLE RISK, INCLUDING RESPONSIBILITY FOR ALL COSTS ASSOCIATED WITH ALL NECESSARY SERVICING OR REPAIRS OF ANY EQUIPMENT YOU USE IN CONNECTION WITH THIS WEB SITE.

TO THE FULL EXTENT NOT PRECLUDED BY APPLICABLE LAW THEIR MEDICAL ADVISORS, SUPPLIERS, CONSULTANTS, DIRECTORS AND EMPLOYEES DISCLAIM AND EXCLUDE ALL WARRANTIES WITH RESPECT TO ALL CONTENT, EXPRESS, IMPLIED OR STATUTORY. THIS DISCLAIMER INCLUDES, BUT IS NOT LIMITED TO, ANY AND ALL WARRANTIES OR MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT. DOES NOT WARRANT THE CONTENT TO BE ACCURATE, COMPLETE OR CURRENT. DOES NOT WARRANT THAT THIS WEB SITE WILL OPERATE WITHOUT ERROR, THAT DEFECTS WILL BE CORRECTED OR THAT THIS WEB SITE OR THE WEB SITE SERVER MAKING IT AVAILABLE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. PRICE AND AVAILABILITY CONTENT, AS WELL AS OTHER CONTENT CONTAINED IN THIS WEB SITE OR ACCESSIBLE THEREFROM, IS SUBJECT TO CHANGE WITHOUT NOTICE.

YOU ACKNOWLEDGE AND AGREE THAT DOES NOT ENDORSE THE CONTENT OF ANY SITE ACCESSED VIA LINKS OR OTHER MEANS FROM THIS WEB SITE AND IT IS NOT RESPONSIBLE OR LIABLE FOR SUCH CONTENT EVEN THOUGH IT MAY BE UNLAWFUL, HARASSING, LIBELOUS, PRIVACY INVADING, ABUSIVE, THREATENING, HARMFUL, OBSCENE, OR OTHERWISE OBJECTIONABLE, OR THAT IT INFRINGES OR MAY INFRINGE THE INTELLECTUAL PROPERTY OR OTHER RIGHTS OF ANOTHER PERSON.

THIS WEB SITE INCLUDES CONTENT PROVIDED BY THIRD PARTIES AND YOU, OUR CUSTOMER. IS A DISTRIBUTOR OF SUCH CONTENT AND NOT ITS PUBLISHER. EDITORIAL CONTROL OF SUCH CONTENT IS THE SAME AS THAT OF A PUBLIC LIBRARY OR NEWSSTAND. THIRD PARTY SUPPLIERS MAY EXPRESS CERTAIN OPINIONS OR PROVIDE CERTAIN INFORMATION AND OFFERS. MAKES NO WARRANTIES AS TO THE COMPLETENESS, ACCURACY, TIMELINESS, OR RELIABILITY OF INFORMATION OR OFFERS SUPPLIED BY THIRD PARTIES. DOES NOT GUARANTEE OR WARRANT THE PERFORMANCE OF ANY THIRD PARTY, INCLUDING ANY SUCH THIRD PARTY’S CONFORMANCE TO ANY LAW, RULE, REGULATION OR POLICY.

DOES NOT WARRANT THAT INFORMATION, SERVICES, AND PRODUCTS CONTAINED IN THIS WEB SITE WILL SATISFY YOUR REQUIREMENTS OR THAT THEY ARE ERROR OR DEFECT-FREE. BEFORE USING ANY PRODUCT YOU SHOULD CONFIRM ANY INFORMATION OF IMPORTANCE TO YOU ON THE PRODUCT PACKAGING. YOU ASSUME RESPONSIBILITY FOR THE ACCURACY, APPROPRIATENESS AND LEGALITY OF ANY INFORMATION YOU SUPPLY

AS PARTIAL CONSIDERATION FOR YOUR ACCESS TO THIS WEB SITE AND USE OF ITS CONTENT, YOU AGREE THAT IS NOT LIABLE TO YOU IN ANY MANNER WHATSOEVER FOR DECISIONS YOU MAY MAKE OR YOUR ACTIONS OR NON-ACTIONS IN RELIANCE UPON THE CONTENT. YOU ALSO AGREE THAT THE AGGREGATE LIABILITY OF ARISING FROM OR RELATED TO YOUR USE AND ACCESS REGARDLESS OF THE FORM OF ACTION OR CLAIM (FOR EXAMPLE, CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY, PROFESSIONAL MALPRACTICE, FRAUD, OR OTHER BASES FOR CLAIMS), IS LIMITED TO THE PURCHASE PRICE OF ANY ITEMS YOU PURCHASED FROM IN THE APPLICABLE TRANSACTION. SHALL NOT IN ANY CASE BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES EVEN IF HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS IS A COMPREHENSIVE LIMITATION OF LIABILITY THAT APPLIES TO ALL LOSES AND DAMAGES OF ANY KIND. IF YOU ARE DISSATISFIED WITH THIS WEB SITE OR ITS CONTENT (INCLUDING TERMS OF USE), YOUR SOLE EXCLUSIVE REMEDY IS TO DISCONTINUE USING THIS WEB SITE. BECAUSE SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES, SUCH LIMITATION MAY NOT BE APPLICABLE TO YOU.

Your Agreement to Abide by All Applicable Laws

By using this Web Site you agree to comply with any and all local, state, or federal laws, statutes, and regulations that relate in any manner to the use of this Web Site and the associated services or products contained thereon.

Relationship between and Users.

and users of our Site are independent contractors, and no agency, partnership, employment or other relationship is created or is intended to be created by the use of our Web Site.

Governing Law and Jurisdiction

This Web Site (excluding linked sites, if any) is administered and controlled by and its affiliates, subsidiaries, officers, directors, employees or agents from its offices in the accordance with the laws of Nevis. You agree that this Terms and Conditions of Use Agreement and this Web Site will be governed by and construed in accordance Nevis law without giving effect to any principles of conflicts of laws. You access this Web Site and/or associated services of at your own risk, and remain responsible for complying with the laws of the jurisdiction within which you are located.

Prices; Payment Terms; Interest

The prices for the products and services on this Web Site are quoted, for convenience, in United States dollars and shall be as set forth in this Web Site as at the time of acceptance of an order by Prices for Products shall be subject to change without any further notice. Credit terms are within sole discretion, and unless otherwise specified in invoice, payment must be received by prior to acceptance of an order.

Consequences

reserves the right to suspend or terminate your account if you violate the Terms of Use Agreement. If your violation causes harm to others, you agree to indemnify and hold harmless from and against any and all loss, damage, or expense. If any dispute arises between us regarding this Agreement or your use of this Web Site, it shall be resolved through good faith negotiations between the parties.

Entire Agreement

These Terms and Conditions and any terms incorporated or referred to herein constitute the entire agreement between and you relating to your use of this Web Site and the subject matter hereof, and supersede any prior understandings or agreements (whether electronic, oral or written) regarding the subject matter, and may not be amended or modified except in writing, or by making such amendments or modifications in accordance with this Terms and Conditions of Use Agreement.

Severability

If any part of this Terms and Conditions of Use Agreement is deemed or determined to be unenforceable, then such part shall be eliminated or limited to the minimum extent necessary. The remainder of this Terms and Conditions of Use Agreement, including any revised portion, shall remain and be in full force and effect. This Terms and Conditions of Use Agreement are the entire agreement between us governing your use of this Web Site.

Headings

The headings contained in this Terms and Conditions of Use Agreement and the Privacy Policy are for reference only.

Force Majeure

shall not be liable for any delay or failure in performance caused by circumstances beyond its reasonable control, including, without limitation, delays due to backorders of requested products, mail delays, customs delays or lost shipments. shall not be responsible to notify the Customer in the event of such delays. The Customer shall be solely responsible to make other arrangements to purchase alternative products and any costs incurred in connection with such purchases.

Thank you again for visiting the Web Site.

Complete Agreement

Except as expressly provided in a particular "legal notice" on this Site, these Terms and Conditions constitute the entire agreement between you and this Site with respect to the use of this Site, and Content. By clicking “I agree” when placing your order, you agree with ALL OF OUR TERMS and CONDITIONS as stated above as well as our Shipping and refunds Policy.

Thank you for your cooperation.

Terms and Conditions of Purchase

Your Use of Our Web Site

Use of Information

DISCLAIMER:

Shipping address will be selected within Apple Pay. Any address entered in checkout will not be used.